Quarterly ResultMay 15, 2026, 04:09 PM
Gossamer Bio Warns Going Concern; Q1 Net Loss $(46.7)M
AI Summary
Gossamer Bio reported a net loss of $46.7 million for the first quarter of 2026, an increase from $36.6 million in the prior year, despite a 71.5% rise in revenue to $17.0 million. The company issued a "going concern" warning, stating that its existing cash and cash equivalents are not sufficient to fund operating plans for at least one year. To address this, Gossamer Bio commenced a workforce reduction of 73 individuals, representing approximately 46% of its staff, incurring $6.1 million in related charges.
Key Highlights
- Issued a "going concern" warning due to insufficient cash to fund operations for at least one year.
- Implemented a workforce reduction of 73 individuals, approximately 46% of its workforce, in Q1 2026.
- Recognized estimated charges of $6.1 million in Q1 2026 related to the workforce reduction.
- Reported a Q1 2026 net loss of $46.7 million, an increase from $36.6 million in Q1 2025.
- Revenue from contracts with collaborators increased 71.5% to $17.0 million in Q1 2026.
- Cash and cash equivalents were $41.0 million as of March 31, 2026.
- Total stockholders' deficit grew to $161.5 million as of March 31, 2026.
- Net cash used in operating activities was $38.7 million in Q1 2026, down from $39.7 million in Q1 2025.
Price Impact
More from GOSS